It has also been shown that sero-conversion (ACPA-positive turning into ACPA-negative) is possible in early RA patients treated with abatacept (ADJUST and AGREE trials) [22,23] suggesting that abatacept may impact on autoantibody formation. This evidence concerns the gene PRTN3 and rheumatoid arthritis.